Kistler-Tiffany Companies’s Esperion Therapeutics ESPR Stock Holding History

Kistler-Tiffany Companies’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$139	Hold	100	–	–	﹤0.01%	882
2023 Q1	$159	Hold	100	–	–	﹤0.01%	781
2022 Q4	$623	Hold	100	–	–	﹤0.01%	762
2022 Q3	$1K	Hold	100	–	–	﹤0.01%	752
2022 Q2	$1K	Hold	100	–	–	﹤0.01%	735
2022 Q1	$0	Hold	100	–	–	﹤0.01%	759
2021 Q4	$1K	Hold	100	–	–	﹤0.01%	698
2021 Q3	$1K	Hold	100	–	–	﹤0.01%	695
2021 Q2	$2K	Hold	100	–	–	﹤0.01%	662
2021 Q1	$3K	Hold	100	–	–	﹤0.01%	592
2020 Q4	$3K	Hold	100	–	–	﹤0.01%	573
2020 Q3	$4K	Hold	100	–	–	﹤0.01%	559
2020 Q2	$5K	Hold	100	–	–	﹤0.01%	505
2020 Q1	$6K	Hold	100	–	–	﹤0.01%	484
2019 Q4	$6K	Hold	100	–	–	﹤0.01%	492
2019 Q3	$4K	Hold	100	–	–	﹤0.01%	523
2019 Q2	$5K	Buy	+100	New	+$4.7K	﹤0.01%	499
2018 Q2	–	Sell	-100	Closed	-$7K	–	576
2018 Q1	$7K	Buy	+100	New	+$7.34K	﹤0.01%	458

Other funds holding ESPR

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Kistler-Tiffany Companies's ESPR Position: Q2 2023 in Review

Kistler-Tiffany Companies held its Esperion Therapeutics (ESPR) position steady in Q2 2023 at 100 shares worth $139. The position accounts for ﹤0.01% of the portfolio, ranked #882.

Kistler-Tiffany Companies first reported a position in ESPR in Q1 2018 and has held it in 18 quarters since. The position peaked at $7K in Q1 2018. 124 funds tracked by Wall St. Rank hold ESPR as of Q2 2023.

Kistler-Tiffany Companies held 100 shares of Esperion Therapeutics worth $139 as of Q2 2023.
Kistler-Tiffany Companies left its Esperion Therapeutics share count unchanged in Q2 2023.
Esperion Therapeutics made up ﹤0.01% of Kistler-Tiffany Companies's portfolio in Q2 2023, its #882 holding.
Kistler-Tiffany Companies first reported a position in Esperion Therapeutics in Q1 2018 and has held it in 18 quarters since.
Kistler-Tiffany Companies's Esperion Therapeutics position peaked at $7K in Q1 2018.
124 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2023.

Based on Kistler-Tiffany Companies's 13F filing for Q2 2023, filed 1 Aug 2023.